These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268 [TBL] [Abstract][Full Text] [Related]
17. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors. Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996 [TBL] [Abstract][Full Text] [Related]
18. Identification of acridinyl hydrazides as potent aspartic protease inhibitors. Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344 [TBL] [Abstract][Full Text] [Related]
19. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum. Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719 [TBL] [Abstract][Full Text] [Related]
20. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum. Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]